NRx Pharmaceuticals (NASDAQ:NRXP) & Biofrontera (NASDAQ:BFRI) Head-To-Head Comparison

Biofrontera (NASDAQ:BFRI – Get Free Report) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Volatility & Risk

Biofrontera has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Biofrontera and NRx Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera 1 1 0 0 1.50
NRx Pharmaceuticals 2 0 6 0 2.50

NRx Pharmaceuticals has a consensus price target of $35.00, indicating a potential upside of 1,498.17%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Biofrontera.

Earnings and Valuation

This table compares Biofrontera and NRx Pharmaceuticals”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biofrontera $41.71 million 0.25 -$10.54 million ($0.45) -1.56
NRx Pharmaceuticals $3.39 million 28.16 -$28.62 million ($0.55) -3.98

Biofrontera has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biofrontera and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biofrontera -12.72% -97.59% -28.37%
NRx Pharmaceuticals -691.81% N/A -63.92%

Institutional & Insider Ownership

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 4.9% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Biofrontera beats NRx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Biofrontera

(Get Free Report)

Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market. The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin. Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a focus on depression and conditions involving suicidal ideation. Its programs are investigational and have not been established as approved treatments. The company’s candidates include NRX-100, a preservative-free formulation of ketamine, and NRX-101, an oral combination of D-cycloserine and lurasidone. NRx has studied these therapies for severe depression and bipolar depression, including in patients with suicidal ideation.

Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.